基本分析
透過季節調整季營收，判斷美股整體趨勢，但注意股價有時候領先基本面的數據，應搭配其他領先指標判斷。
基本資料
個股的基本資料，以及所屬的類股和產業。
公司介紹
業務介紹
優力基因製藥公司是一家生物製藥公司,專注於在北美、歐洲和國際上識別、收購、開發和商業化用於治療罕見和超罕見遺傳性疾病的創新產品。其生物製品包括:
1. Crysvita (burosumab),一種針對纖維母細胞生長因子23的抗體,用於治療X連鎖性低磷酸酶血症和腫瘤引起的骨軟化症。
2. Mepsevii,一種酶替代療法,用於治療兒童和成人粘多糖症VII型。
3. Dojolvi,用於治療長鏈脂肪酸氧化障礙。
4. Evkeeza (evinacumab),用於治療家族性高膽固醇血症。
該公司的產品候選藥物包括:
1. DTX401,一種腺相關病毒8型(AAV8)基因療法臨床候選藥物,用於治療I型糖原儲積病。
2. DTX301,一種AAV8基因療法,用於治療鳥氨酸轉羧酶缺乏症。
3. UX143,一種用於治療成骨不全的人源單克隆抗體。
4. GTX-102,一種用於治療安吉爾曼綜合症的反義寡核苷酸。
5. UX701,用於治療威爾遜病。
6. UX053,用於治療III型糖原儲積病。
優力基因製藥公司成立於2010年,總部位於加州諾瓦托。
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
警語
1. 資料僅供參考，不做任何獲利保證及特定股票與點位推薦建議。
2. 資料並不完整，需要完整資料請至相關網站索取。
3. 任何股市數據分析皆存在倖存者偏差。
